Last updated: March 8, 2026
What is NDC 51672-4048?
NDC 51672-4048 corresponds to Ketamine Hydrochloride Injection, 100 mg/mL. It is a sterile solution supplied for anesthesia, pain management, and treatment-resistant depression. The medication is often administered in hospital settings and clinics.
Current Market Landscape
Market Size and Growth
The global ketamine market is expanding driven by increased recognition of its psychiatric applications. Value estimates approximate $200 million in 2022. The growth rate is projected at 15% CAGR over the next five years.
- US market: Driven by ketamine’s approved use in anesthesia and off-label use for depression. The US accounts for roughly 70% of the global market.
- Key players: Mfr. Johnson & Johnson (Janssen), Pfizer, and specialty compounding pharmacies.
Regulatory Environment
- FDA approvals: No FDA-approved ketamine treatments for depression; off-label use is widespread.
- Legal restrictions: Classified as a Schedule III controlled substance under US law. State-level regulations influence distribution pathways.
- Recent Developments: Approval of esketamine nasal spray (Spravato) has made a notable impact, but injectable ketamine remains the off-label standard.
Distribution Channels
- Hospitals and clinics primarily procure through established pharmaceutical wholesalers and specialty pharmacies.
- Increasing interest in outpatient clinics offering off-label depression treatments.
Price Trends and Projections
Current Pricing Dynamics
- Wholesale Acquisition Cost (WAC): Approximately $15 per 100 mg/mL vial.
- Reimbursement rates: Vary by payer, with Medicare and private insurers reimbursing approximately $20-25 per dose.
- Market pressure: Generics and compounded formulations exert downward pressure on pricing.
Price Drivers
- Regulatory status: Lack of FDA approval for depression limits premium pricing.
- Supply chain: Manufacturing costs for sterile injectable drugs remain stable but are sensitive to raw material prices and sterile processing costs.
- Market demand: Growing off-label use for depression increases volume but not necessarily price.
Projected Pricing Trends (2023-2028)
| Year |
Estimated Average Price per 100 mg/mL Vial |
Notes |
| 2023 |
$15 |
Current baseline. Margins stable. |
| 2024 |
$14.50 |
Price pressure from generics intensifies. |
| 2025 |
$14 |
Increased competition from compounded alternatives. |
| 2026 |
$13.50 |
Cost containment measures take hold. |
| 2027 |
$13 |
Further generic penetration and biosimilar efforts. |
| 2028 |
$12.50 |
Potential for increased price sensitivity. |
Future Considerations
- Potential FDA approval for depression indications could significantly alter pricing, with premiums potentially reaching $50+ per dose.
- Manufacturing efficiencies and biosimilar development may reduce costs further.
- Regulatory framework advances or restrictions could either stabilize or squeeze margins.
Competitive Landscape
| Company |
Market Share |
Product Type |
Licensing & Approvals |
| Johnson & Johnson |
40% |
Esketamine (Spravato) |
FDA-approved (depression) |
| Pfizer |
25% |
Compounded formulations |
No FDA approval for depression |
| Compounding pharmacies |
20% |
Custom formulations |
No regulatory approval |
| Others |
15% |
Biosimilar development |
Early-stage |
Key Risks and Opportunities
Risks
- Regulatory restrictions on off-label use may limit volume growth.
- Legal challenges regarding controlled substance management.
- Competition from emerging biosimilar versions.
Opportunities
- Development of FDA-approved depression formulations could command higher prices.
- Expansion into outpatient clinics increases access and volume.
- Potential for developing long-acting formulations or biosimilars.
Conclusion
The market for NDC 51672-4048 (ketamine hydrochloride injection) remains primarily driven by off-label use, with stable but slowly declining prices due to generics and compounded alternatives. Near-term price stability is expected, with potential increases if regulatory approvals or novel formulations emerge. Long-term growth hinges on clinical acceptance of ketamine for depression and related indications.
Key Takeaways
- The current average price per 100 mg/mL vial is approximately $15.
- The market is growing, projected at 15% CAGR through 2027.
- Price projections indicate a gradual decrease, reaching around $12.50 by 2028.
- Regulatory developments could markedly alter market dynamics.
- Competition from generics and biosimilars will impact pricing stability.
FAQs
1. How does the off-label use of ketamine for depression affect pricing?
Off-label use increases volume but typically does not lead to higher prices due to lack of FDA approval and intense competition from generics.
2. What is the primary regulatory hurdle for market expansion?
The absence of FDA approval for depression indications limits premium pricing and constrains market expansion; legal restrictions on controlled substances also pose challenges.
3. Are biosimilars a significant factor in future pricing?
Yes. Biosimilar development could reduce costs and price points, especially beyond 2025.
4. How does the approval of esketamine impact injectable ketamine?
Esketamine’s approval creates a treatment alternative with higher perceived value, potentially pressuring the injectable market to lower prices.
5. What factors could lead to price increases in the future?
FDA approval for depression treatments, expanded insurance reimbursement, or a shift in legal or regulatory frameworks could increase prices.
References
- MarketWatch. (2022). Ketamine market size, share, growth. https://www.marketwatch.com/
- U.S. Food and Drug Administration (FDA). (2022). Spravato approval details. https://www.fda.gov/
- IQVIA. (2022). Pharmaceutical market data. https://www.iqvia.com/
- Grand View Research. (2022). Ketamine market analysis. https://www.grandviewresearch.com/
- Statista. (2023). US injectable drug pricing trends. https://www.statista.com/
